

# TRABID CD(245-697) [6His-tagged]

Deconjugating enzyme: Deubiquitylase

Alternate Names: TRAF binding protein domain, Zinc finger RAN binding domain containing 1, ZRANB1

Cat. No. 64-0049-050

Lot. No. 30166

Quantity: 50 µg

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

## Background

Deconjugating enzymes (DCEs) are proteases that process ubiquitin or ubiquitin-like gene products, reverse the modification of proteins by a single ubiquitin or ubiquitin-like protein (UBL) and remodel polyubiquitin (or poly-UBL) chains on target proteins (Reyes-Turcu *et al.*, 2009). The deubiquitylating – or deubiquitinating – enzymes (DUBs) represent the largest family of DCEs and regulate ubiquitin dependent signalling pathways. The activities of the DUBs include the generation of free ubiquitin from precursor molecules, the recycling of ubiquitin following substrate degradation to maintain cellular ubiquitin homeostasis and the removal of ubiquitin or ubiquitin-like proteins (UBL) modifications through chain editing to rescue proteins from proteasomal degradation or to influence cell signalling events (Komander *et al.*, 2009). There are two main classes of DUB, cysteine proteases and metalloproteases. TRABID is a cysteine protease and is a member of the OTU (ovarian tumour) superfamily of proteins (Balakirev *et al.*, 2003). Cloning of the human gene was first described by Evans *et al.* (1992). TRABID was recently reported to specifically and positively regulate the Wnt signalling pathway. TRABID is composed of a tumour necrosis factor receptor associated factor (TRAF) binding domain in the C-terminus and three Zinc-finger (ZnF) motifs at the N-terminus. TRABID preferentially binds to K63-linked polyubiquitin chains but not K48-linked polyubiquitin chains and specifically cleaves

## Physical Characteristics

**Species:** human

**Source:** *E. coli*

**Quantity:** 50 µg

**Concentration:** 0.5 mg/ml

**Formulation:** 50 mM HEPES pH 7.5,  
150 mM sodium chloride,  
2 mM dithiothreitol, 10% glycerol

**Molecular Weight:** ~54.8 kDa

**Purity:** >81% by InstantBlue™ SDS-PAGE


**Stability/Storage:** 12 months at -70°C;  
aliquot as required

**Protein Sequence:** Please see page 2

## Quality Assurance

### Purity:

4-12% gradient SDS-PAGE  
InstantBlue™ staining  
Lane 1: MW markers  
Lane 2: 1 µg His-TRABID  
CD(245-697)



### Protein Identification:

Confirmed by mass spectrometry.

### Deubiquitylase Enzyme Assay:

The activity of His-TRABID CD(245-697) was validated by the monitoring of mono-ubiquitin generation as a result of the enzyme catalysed cleavage of K63-linked di-ubiquitin. Incubation of the substrate in the presence or absence of His-TRABID CD(245-697) was compared confirming the deubiquitylating activity of His-TRABID CD(245-697).

Continued on page 2



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

International: +1-617-245-0003  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2013. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

# TRABID CD(245-697) [6His-tagged]

## Deconjugating enzyme: Deubiquitylase

Alternate Names: TRAF binding protein domain, Zinc finger RAN binding domain containing 1, ZRANB1

Cat. No. 64-0049-050  
Lot. No. 30166

Quantity: 50 µg  
Storage: -70°C



FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 2 of 2

### Background

Continued from page 1

K63 chains. K63-linked ubiquitylation is known to fulfil diverse proteasome-independent roles, including DNA repair, endocytosis and NFκB signalling (Shi *et al.*, 2012). Proteins that mediate specific assembly and disassembly of atypical K6, K27, K29 and K33 linkages are mainly unknown. Recent work on these atypical di-ubiquitins has shown that TRABID specifically hydrolyses both K29 and K33-linked di-ubiquitin (Licchesi *et al.*, 2012) and in fact cleaves the K29 linkage with 40-fold more efficiency than the K63 linkage (Virdee *et al.*, 2010)

#### References:

Komander D, Clague MJ and Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* 10, 550-563.

Licchesi JD, Mieszczanek J, Mevissen TE, Rutherford TJ, Akutsu M, Virdee S, *et al.* (2012) An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. *Nature Structural & Molecular Biology* 19, 62-71.

Nakamura T, Hillova J, Mariage-Samson R, Onno M, Huebner K, Cannizzaro LA, *et al.* (1992) A novel transcriptional unit of the *trc* oncogene widely expressed in human cancer cells. *Oncogene* 7, 733-741

Reyes-Turcu FE, Ventii KH and Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. *Ann Rev Biochem* 78, 363-397.

Shi T, Bao J, Wang NX, Zheng J and Wu D (2012) Identification Of Small Molecule TRABID Deubiquitinase Inhibitors By Computation-Based Virtual Screen. *BMC Chem Biol* 12, 4.

Virdee S, Ye Y, Nguyen DP, Komander D and Chin JW (2010) Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. *Nature Chemical Biology* 6, 750-757.

### Physical Characteristics

Continued from page 1

#### Protein Sequence:

**MGSSHHHHHSSG**LEVL**FQ**GPS**LE**VDFK  
KLKQIKNRMKKTDLWFLNACVGVVEGD  
LAAIEAYKSSGGDIARQLTADEVRLNRP  
SAFDVGYTLVHLAIRFQRQDMLAILLTE  
VSQQAAKCI PAMVCP E L T E Q I R R E  
IAASLHQKRGDFACYFLTDLVTF T L P A D  
IEDLPPTVQEKLFDEVLD R D V Q K E L E E E S P I  
INWSLELATRLDSRLYALWNR TAG D C L L D S  
VLQATWGIYDKDSVLRKALHDSLHDCSHW  
FYTRKDWESWYSQSFGLHFSLREEQWQED  
WAFILSLASQPGASLEQTHIFVLAHILRRPI  
IVYGVKYYKSF R G E T L G Y T R F O G V Y L P L L  
WEQSF C W K S P I A L G Y T R G H F S A L V A  
MENDGYGNRGAGANLNTDDDV T I T F L P L V D  
SERKLLHVHFLSAQELGNEEQQEKLLREWLDC  
CVTEGGVLVAMQKSSRRRNHPLVTQMVEKWL D  
RYRQIRPCTSL S

Tag (**bold text**): N-terminal His

Protease cleavage site: PreScission™ (LEVL**FQ**▼GP)

TRABID CD(246-697) (regular text): Start **bold italics** (amino acid residues 245-697)

Accession number: NP\_060050



www.ubiquigent.com  
Dundee, Scotland, UK

#### ORDERS / SALES SUPPORT

International: +1-617-245-0003  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

#### UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2013. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0